Shares of AnaptysBio, Inc. (ANAB) are down more than 34% Monday morning after the clinical-stage biotechnology company announced negative top-line results from the mid-stage study of its lead drug candidate imsidolimab, for the treatment of palmoplantar pustulosis.
The phase II study of imsidolimab, dubbed Poplar, in moderate-to-severe palmoplantar pustulosis, a chronic skin condition with blisters on palms and soles, failed to meet its primary endpoint.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.